Jazz Pharmaceuticals Q3: Strong Revenue, Mixed Profitability

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded12 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2196875

Show notes

Jazz Pharmaceuticals Q3 earnings surpassed expectations with $1.13 billion in revenue and $8.13 in adjusted earnings per share, driven by strong demand for Xywav, Epidiolex, and Modeyso. The companys CEO, Renée Galá, highlighted recent FDA approvals and positive developments in sleep and oncology divisions. However, adjusted EBITDA and operating margin fell short of forecasts. Jazz reaffirmed full-year revenue guidance and raised adjusted earnings per share guidance. The company is monitoring generic competition for Xyrem and preparing for cancer drug trial data releases.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.